Drug Trial Radar · NCT05907746
Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Deficiency
Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
13
Actual
Start
Nov 29, 2023
Primary completion
Oct 16, 2025
Study completion Jul 31, 2028
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Jun 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Background: People with GATA-binding factor 2 (GATA2) deficiency have a mutation on the GATA2 gene. This gene affects immune function. People with this disease are prone to serious infections; in time, they may develop blood cancers. A hematopoietic stem cell (HSC) transplant can cure GATA2 deficiency, but using stem cells donated by other people can cause serious side effects. Objective: To test a new drug (Briquilimab) to see if it can make HSC transplants safer. Eligibility: People aged 6 to 70 years who have GATA2 deficiency. Design: Participants will be screened. They will have a physical exam, with blood and urine tests. They will have tests of their heart and lung function. They may have a bone marrow biopsy: Their hip will be numbed; a large needle will be inserted to draw out tissue from inside the pelvis. Participants will have a central venous catheter placed in a vein of the neck or chest. This will be used to draw blood and administer drugs. Briquilimab will be given through the catheter about 11 days before the transplant. This is part of conditioning: preparing the body to receive the new stem cells. Conditioning also includes other medications and total body irradiation. Donor stem cells will be administered through the catheter. Participants will receive other approved drugs to help prevent side effects. Participants will stay in the hospital from the beginning of the conditioning until several weeks after the transplant. They will remain in the local area for 100 days after discharge; they will come to the clinic at least once a week during this time. Follow-up visits will continue for 3 years....
Conditions
- GATA2
- Immunodeficiency
Interventions
Mycophenolate MofetilDrug
15 mg/kg intravenous (IV) three times per day starting on day +5 until approximately day +30 (+/- 2 days)
TacrolimusDrug
0.02 mg/kg intravenous (IV) daily starting on day +5
Post-Transplant CyclophosphamideDrug
50 mg/kg intravenous (IV) daily on days +3 and +4
Total Body IrradiationRadiation
200 centigray (cGy) on day -1
Hematopoietic Cell TransplantProcedure
Stem cell transplant on day 0
BriquilimabDrug
Single 0.6 mg/kg intravenous (IV) infusion administered between days -13 and day -10
CyclophosphamideDrug
14.5 mg/kg intravenous (IV) daily on days -6 and -5; for 7/8 Unrelated or Haploidentical Donor, prior to transplant.
FludarabineDrug
30 mg/m\^2 intravenous (IV) over 30 minutes daily. For 8/8 Matched Related or Unrelated Donor, fludarabine dose will be on days -4, -3, and -2. For 7/8 Unrelated or Haploidentical Donor, fludarabine dose will be on days -6, -5, -4, -3, and -2.
Bone Marrow BiopsyProcedure
Screening ≤90 days.
Bone Marrow AspirateProcedure
Screening ≤90 days.
2D echoDiagnostic test
Screening ≤90 days.
EKGDiagnostic test
Screening ≤90 days.
PFT'sProcedure
Screening ≤90 days.
CT scan of chest, abdomen and pelvisDiagnostic test
Baseline ≤28 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Evaluable Participants With GATA-binding Factor 2 (GATA2) Deficiency With Sustained Donor Engraftment by 100 Days Post-transplant Reported Along With a Two-sided 90% Confidence IntervalTime frame: 100 days
- Percentage of Evaluable Participants With GATA-binding Factor 2 (GATA2) Deficiency With Sustained Donor Engraftment by 100 Days Post-transplant Reported Along With a Two-sided 95% Confidence IntervalTime frame: 100 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Institutes of Health Clinical Center
Bethesda, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.